Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sernova Corp T.SVA

Alternate Symbol(s):  SEOVF

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases requiring replacement of these molecules in the body.


TSX:SVA - Post by User

Comment by Redbaron2211on Apr 02, 2021 12:40pm
111 Views
Post# 32932201

RE:RE:RE:Dr. Toleikis deserves our Respect and Vote

RE:RE:RE:Dr. Toleikis deserves our Respect and Vote
 

Red,

Holler was is charge of a fund where Matthews worked . Matthews  brought Holler over . Angiotech turned out to be a disaster after their sale and lawsuits to Boston Scientific. I surely hope you don't want the failure of Angiotech.  Tolekis was Vice President in Science side , he was not in the board room negotiating anything . Proves my point Tolekis has no business acumen . He  has does done a great job getting the company to this point and am sure is a fine person, but you need experienced management that can stick handle through with pharma and licensing deals.

Red  I heard a rumour and you should ask Philip or Dominic directly that the group that did the previous pp at higher sp at 30 which was higher than the sp and did not charge any commissions apparently would have done it he raise at much favourable levels . Tolekis apparently did not even take offer sheets from competing firms .   That's the rumour .

Red if this is true then you need to open your eyes and see that your investment will not achieve its full potential. How do you not know managements abolity when it comes to do a pharma or iicensing deal that they will not give it away like they did with the financing ?

You have to look at all angles of your investment . All risks and mangement is the biggest risk so far in my opinion .  



MustangSally

that's respectable.  I won't argue that Ray wasn't involved in bringing over Frank but I have to look at it in the context that Frank and Philp were already well acquainted decades before.

Anyways I see where this is coming from now.  To be honest I have no idea why the decisions were made but I see the bread crumbs like Canaccord acting as a bookrunner in Sigilons IPO and have to trust that the right decisions were made.

For me to take a step back and look at my investment I do see management weakness as a risk and feel this can be mitigated now that we have some money to bring on more tallant and fill a position like a CMO.  

Anyways if Tolekis didnt look at any other offers I feel like this deal was already done, it would be incredibly short sighted otherwise. 
<< Previous
Bullboard Posts
Next >>